MaxCyte ( (MXCT) ) just unveiled an update.
MaxCyte, Inc., a non-UK issuer, has announced a change in its major holdings, as BlackRock, Inc. has adjusted its voting rights in the company. This adjustment indicates an increase in BlackRock’s voting rights attached to shares and through financial instruments, reaching a total of 7.64%. This development reflects BlackRock’s strategic interest in MaxCyte, potentially impacting the company’s governance and investor relations.
More about MaxCyte
YTD Price Performance: 12.65%
Average Trading Volume: 63,623
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £396.9M
For an in-depth examination of MXCT stock, go to TipRanks’ Stock Analysis page.